Onivyde, a liposomal irinotecan injection, is used to treat pancreatic cancer. It is administered intravenously [1].
How is Onivyde administered?
Onivyde is given as an infusion into a vein over 90 minutes. The dosage and frequency depend on the patient's condition and response to treatment [1].
What are the recommended doses for Onivyde?
The recommended dose of Onivyde is 70 mg/m² administered every two weeks for 4 doses. This is followed by a two-week break [1].
What are the side effects of Onivyde?
Common side effects of Onivyde include diarrhea, fatigue, vomiting, decreased appetite, and stomatitis. Severe side effects can include severe diarrhea, dehydration, electrolyte imbalance, and blood disorders [1].
What precautions should be taken with Onivyde?
Patients should be monitored for severe diarrhea, and treatment may need to be adjusted or stopped. Patients also need to be monitored for bone marrow suppression and signs of infection [1].
What clinical trials support the use of Onivyde?
Onivyde's approval was based on a clinical trial that showed a significant improvement in overall survival for patients treated with Onivyde plus fluorouracil and leucovorin compared to those treated with fluorouracil and leucovorin alone [1].
Who manufactures Onivyde?
Ipsen Biopharmaceuticals, Inc. manufactures Onivyde [1].